GSKCONS

GlaxoSmithKline Consumer Healthcare Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Jun-2015.

The Exchange has sought clarification GlaxoSmithKline Consumer Healthcare Limited with respect to recent news item captioned "FSSAI orders testing of GSK, ITC fast food brands". In this regard, the Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following : Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The reply from the Company is awaited.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that the date of commencement of closing of Trading Window shall be from June 15, 2015 and shall end 48 hours after public announcement of the Quarterly Financial Results for the first quarter (FY 2015 2016).

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that the Board of Directors at their meeting held on May 8, 2015 formulated and adopted the Code of Conduct and Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information of Company in compliance with the regulation 8 of the SEBI (Prohibition of Insider Trading) Regulations, 2015. Further, the Code of Conduct and Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information has also been published on the website of the Company.

GlaxoSmithKline Consumer Healthcare Limited has submitted to the exchange the standalone financial results for the period ended 31-Mar-2015.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from July 29, 2015 to August 6, 2015 (both days inclusive) for the purpose of dividend and Annual General Meeting (AGM) of the Company to be held on August 6, 2015.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that Mr. Manoj Kumar has been appointed as the Managing Director of the Company in place of Mr. Zubair Ahmed with effect from June 1, 2015 under the provisions of Article 97 A of the Articles of Association of the Company and approved by the Board of Directors at its meeting held on May 8, 2015. Board noted the withdrawal of nomination by Horlicks Limited of Mr. Zubair Ahmed as the Director of the Company with effect from the close of business hours on May 31, 2015 and accepted his resignation. The Board had also appo

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that the Board recommended a Dividend at the rate of Rs. 55/- per equity share of Rs. 10 each.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that the dividend shall be paid to the entitled Members on or before September 5, 2015.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that Mr. Ramakrishnan Subramanian, consequent to his promotion to a global role, has resigned as Director Finance and Chief Financial Officer of the Company with effect from the closing hours of May 31, 2015.

Horlicks Limited has submitted to the Exchange vide letter dated April 02, 2015 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

GlaxoSmithKline Pte. Limited has submitted to the Exchange vide letter dated April 07, 2015 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that the date of commencement of closing of "Trading Window" shall be from March 15, 2015 and shall end 24 hours after declaration of Audited / Unaudited Financial Results (FY 2014-2015).

GlaxoSmithKline Consumer Healthcare Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 31-Dec-2014.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that in accordance with the Company's Policy on Insider Trading the of commencement of closing of "Trading Window" shall be from December 15, 2014 and shall end 24 hours after public announcement of the Quarterly Financial Results for the third quarter (FY 2014-2015).

GlaxoSmithKline Consumer Healthcare Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Sep-2014.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding a press release dated October 08, 2014, titled "Zubair Ahmed appointed designate Head of Asia Pacific, Middle East and Africa operations of GlaxoSmithKline Consumer Healthcare ".

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange a copy of Minutes of the Annual General Meeting of the Company held on August 07, 2014.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the details of results of e-voting and poll of the Annual General Meeting.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that at the Annual General Meeting of the Company held on August 7, 2013, the Chairman ordered a poll on all the resolutions mentioned in the Notice of the Annual General Meeting. The details of the voting results of the poll ordered at the Annual General Meeting and the electronic voting on all the resolutions contained in the Notice, shall be forwarded on the receipt of the report of the scrutinizers.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on August 06, 2014 on the recommendation of the Nomination & Remuneration Committee, appointed Ms. Sangeeta Talwar, as an Independent Director of the Company, in the casual vacancy created by the resignation of Ms. Ireena Vittal.

GlaxoSmithKline Consumer Healthcare Limited has submitted to the exchange the standalone financial results for the period ended 30-Jun-2014.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that in accordance with the Company's Policy on Insider Trading, the date of commencement of closing of "Trading Window" shall be from July 03, 2014 and shall end 24 hours after public announcement of the Quarterly Financial Result for the first quarter (FY 2014 - 2015).

GlaxoSmithKline Consumer Healthcare Limited had informed the Exchange that the Company has fixed Book Closure from July 29, 2014 to August 7, 2014 for the purpose of Payment of Dividend & Annual General Meeting of the Company to be held on August 07, 2014. The Company has now informed the Exchange that as July 29, 2014 is a holiday, the date of Book closure is being revised. The Company has fixed revised Book Closure from July 31, 2014 to August 7, 2014 (both days inclusive) for the purpose of dividend and AGM.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that pursuant to the provisions of Section 108 of the Companies Act, 2013 and Rule 20(3)(vii) of the Companies (Management & Administration) Rules, 2014, the Company has fixed June 27, 2014 as the cut-off date to record the entitlement of the shareholders to cast their vote electronically at the Annual General Meeting (AGM) by electronic means under the Companies Act, 2013 and rules made there under. Consequently, the same cut-off date of June 27, 2014 would record entitlement of the shareholders, who do not cast their vote

The Exchange had sought clarification from GlaxoSmithKline Consumer Healthcare Limited with respect to news item captioned "GSK Consumer fined for overcharging". The Company has clarified that "No comments as Crocin is not a brand of the listed entity GlaxoSmithKline Consumer Healthcare Limited. We would like to state that Crocin is GlaxoSmithKline Asia Private Limited s brand and is not related to the listed entity GlaxoSmithKline Consumer Healthcare Limited. Therefore, there is no material impact of this article on the Company".

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that the Company has fixed Book Closure from July 29, 2014 to August 7, 2014 for the purpose of Payment of Dividend & Annual General Meeting of the Company to be held on August 07, 2014.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 09, 2014,has recommended a Dividend at the rate of Rs. 45/- per equity share of Rs. 10 each. The dividend shall be paid to the entitled Members on or before September 05, 2014.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the standalone Results for the period ended on 31-MAR-2014 as follows: Net Sales of Rs. 468292 lacs for period ending on 31-MAR-2014. Net Profit / (Loss) of Rs. 67476 lacs for the period ending on 31-MAR-2014.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2014 as follows: Net Sales of Rs. 107909 lacs for the quarter ending on 31-MAR-2014 against Rs. 93986 lacs for the quarter ending on 31-MAR-2013. Net Profit / (Loss) of of Rs. 17171 lacs for the quarter ending on 31-MAR-2014 against Rs. 15641 lacs for the quarter ending on 31-MAR-2013.

GlaxoSmithKline Consumer Healthcare Limited has submitted to the exchange the standalone financial results for the period ended 31-Mar-2014.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that Ms Ireena Vittal, Independent Director of the Company has resigned w.e.f. May 1, 2014 and NOT 2013. Due to a typographical error in our earlier communication the effective date of resignation was wrongly mentioned as w.e.f. May 1, 2013.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange Ms. Ireena Vittal, Independent Director of the Company has resigned w.e.f. May 1, 2013.

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange that GSK Plc and Novartis AG have entered into an agreement to create Consumer Healthcare Joint Venture to hold GSK s Consumer Healthcare business and Novartis OTC Consumer Healthcare business. This Consumer Healthcare Joint Venture will exclude GlaxoSmithKline Consumer Healthcare Limited India, where GSK plc will continue to hold directly its interests in the listed entity.

GlaxoSmithKline Consumer Healthcare Limited has submitted to the exchange the standalone financial results for the period ended 31-dec-2013.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2013 as follows: Net Sales of Rs. 83911 lacs for the quarter ending on 31-DEC-2013 against Rs. 97194 lacs and Rs. 70907 lacs for the quarters ending on 30-SEP-2013 and 31-DEC-2012 respectively. Net Profit / (Loss) of Rs. 7975 lacs for the quarter ending on 31-DEC-2013 against Rs. 14693 lacs and Rs. 6965 lacs for the quarters ending on 30-SEP-2013 and 31-DEC-2012 respectively.

GlaxoSmithKline Consumer Healthcare Limited has submitted to the exchange the standalone financial results for the period ended 30-sep-2013.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that Ms. Sonali Khanna has been appointed as the Company Secretary w.e.f. August 01, 2013 in place of Mr. Surinder Kumar, who had decided to step down as the Company Secretary of the Company.Further, Ms. Sonali Khanna shall also act as the Compliance Officer with effect from August 01, 2013

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2013 as follows: Net Sales of Rs. 85292 lacs for the quarter ending on 30-JUN-2013 against Rs. 93986 lacs and Rs. 72973 lacs for the quarters ending on 31-MAR-2013 and 30-JUN-2012 respectively. Net Profit / (Loss) of Rs. 11996 lacs for the quarter ending on 30-JUN-2013 against Rs. 15641 lacs and Rs. 10660 lacs for the quarters ending on 31-MAR-2013 and 30-JUN-2012 respectively.

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange the Standalone Financial Results alongwith Limited Review Report for the period ended June 30,2013.

Arisaig Partners (Asia) Pte. Ltd. has submitted to the Exchange vide letter dated June 13, 2013 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure pursuant to Regulations 13(3) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended March 31,2013.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 01, 2013, has noted the withdrawal of nomination by Horlicks Limited of Mr.Simon Scarff as the Director of the Company and as the Chairman of the Board w.e.f. close of business hours as on April 30, 2013 & accepted the resignation of Mr.Subodh Bhargava as an elected Director. The Board appointed Ms.Ireena Vittal as a Director of the Company, in the casual vacancy caused by the resignation of Mr.Subodh Bhargava. Pursuant to Article 97A of the Articles of As

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange vide letter dated April 23, 2013 a copy of Minutes of the Annual General Meeting of the Company held on April 09, 2013.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that at the Board Meeting held on Tuesday, April 9, 2013 Mr. Simon Scarff, Chairman of the Board of Directors, has expressed his desire to step down as the Chairman of the Company w.e.f. close of business hours on April 30, 2013.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the Outcome of Annual General Meeting held on April 09, 2013.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the details of Voting results at the 54th Annual General Meeting (AGM) of the Company held on April 09, 2013, under Clause 35A.

Life Insurance Corporation of India has informed the Exchange vide letter dated February 18, 2013 that "As per the guideline on Institutional Transactions in shares issued by Govt. of India on February 20, 1990, we hereby inform that Life Insurance Corporation of India has sold 16,71,579 equity shares (of face value of Rs.10/- each) of GlaxoSmithkline Consumer Healthcare Ltd. @ Rs.3900/- per share".

GlaxoSmithKline Pte Ltd has submitted to the Exchange, vide letter dated February 13, 2013 a copy of Disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that the Company has fixed Book Closure from March 21, 2013 to April 9, 2013 both days inclusive for the purpose of Dividend and the Annual General Meeting